Compare RZLT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RZLT | RLMD |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.1M | 348.8M |
| IPO Year | 2011 | 2012 |
| Metric | RZLT | RLMD |
|---|---|---|
| Price | $4.00 | $3.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $10.40 | ★ $10.75 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.47 | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,517.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $1.07 | $3.07 |
| 52 Week High | $11.17 | $8.00 |
| Indicator | RZLT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 36.77 |
| Support Level | $3.58 | N/A |
| Resistance Level | $4.22 | $3.55 |
| Average True Range (ATR) | 0.36 | 0.43 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 35.74 | 1.45 |
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.